World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
51589
World Ranking
10260
National Ranking
987

Jonathan A. Ledermann publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jonathan A. Ledermann sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 442 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jonathan A. Ledermann D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jonathan A. Ledermann sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • Fellow of The Academy of Medical Sciences, United Kingdom
  • Fellow of The Academy of Medical Sciences, United Kingdom

Overview

Jonathan A. Ledermann is affiliated with University College London in the United Kingdom. Their research primarily spans the field of Medicine, with significant contributions to subfields such as Reproductive Medicine, Oncology, Genetics, Obstetrics and Gynecology, and Pulmonary and Respiratory Medicine.

The scientist has authored numerous papers, focusing especially on cancer treatments and associated diagnostics. Key recent publications include:

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma, 2020, International Journal of Gynecological Cancer
  • Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2022, Annals of Oncology
  • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer, 2020, Annals of Oncology
  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial, 2021, The Lancet Oncology
  • Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study, 2021, The Lancet Oncology

Frequent co-authors collaborating with Jonathan A. Ledermann include:

  • Amit M. Oza
  • Nicoletta Colombo
  • Clare L. Scott
  • Chunxue Bai
  • Joseph Bauer

The scientist's work is often published in several high-impact journals, such as:

  • Cancer
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • Gynecologic Oncology
  • Journal of Clinical Oncology

Main research topics addressed by their work include:

  • Ovarian cancer diagnosis and treatment
  • PARP inhibition in cancer therapy
  • Endometrial and Cervical Cancer Treatments
  • BRCA gene mutations in cancer
  • Toxin Mechanisms and Immunotoxins
  • Intraperitoneal and Appendiceal Malignancies
  • Cancer Immunotherapy and Biomarkers

Jonathan A. Ledermann was recognized as a Fellow of The Academy of Medical Sciences in the United Kingdom. Their career reflects extensive research activity and collaboration within the medical oncology community, with special emphasis on gynecologic cancers and targeted therapies.

Best Publications

  • ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

    Nicoletta Colombo;Carien Creutzberg;Frederic Amant;Tjalling Bosse

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Mansoor R. Mirza;Bradley J. Monk;Jørn Herrstedt;Amit M. Oza

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

    MK Parmar;JA Ledermann;N Colombo;Bois A Du

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.

    Nicole Concin;Xavier Matias-Guiu;Ignace Vergote;David Cibula

  • Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J.A. Ledermann;F.A. Raja;C. Fotopoulou;A. Gonzalez-Martin

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    N. Colombo;C. Sessa;A. du Bois;J. Ledermann

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

    Roger D James;Robert Glynne-Jones;Helen M Meadows;David Cunningham

  • Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

    Matthew T Seymour;Timothy S Maughan;Jonathan A Ledermann;Clare Topham

  • Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

    Theo Ruers;Frits Van Coevorden;Cornelis J. A. Punt;Jean-Pierre E. N. Pierie

  • Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

    Stephanie M. de Boer;Melanie E. Powell;Linda Mileshkin;Dionyssios Katsaros

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference

    Gavin C.E. Stuart;Henry Kitchener;Monica Bacon;Andreas duBois

  • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Jonathan A Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.

    N Colombo;N Colombo;C Sessa;A du Bois;J Ledermann

Frequent Co-Authors

Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Michael Friedlander
Michael Friedlander University of New South Wales
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Iain A. McNeish
Iain A. McNeish Imperial College London
Giovanni Scambia
Giovanni Scambia Catholic University of the Sacred Heart
Robert L. Coleman
Robert L. Coleman The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA can open doors to many related healthcare fields and flexible career paths. Prospective students don’t always have to follow the traditional medical school route and, thanks to online learning, there are more accessible options than ever.

For instance, if you are considering nursing, you may wonder do all nursing schools require the teas? Some top schools offer programs without the TEAS or HESI exam requirement, making admission more attainable.

Those interested in healthcare leadership roles might look into a degree in healthcare administration, which prepares graduates for high-demand management positions in hospitals and health systems.

Registered nurses aiming to advance their practice can pursue rn to fnp bridge programs. These online bridge degrees help nurses become Family Nurse Practitioners, broadening their scope of practice.

If you have a passion for food and health, consider the best online food science degree options. These programs lead to careers in nutrition, wellness, and food safety.

Exploring these online healthcare pathways can offer flexibility and specialization, helping you build a rewarding career that fits your goals.

Best Scientists Citing Jonathan A. Ledermann

Trending Scientists

Recently Published Articles